Food and Drug Administration (FDA) Blogs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

For Those Who Are Serious About Increasing Access to MAT for Opioid Use Disorder …
The synthetic opioid methadone, developed in Germany in the 1930s for the treatment of severe pain, has been employed for the Medication Assisted Treatment (MAT) of heroin addiction and opioid use disorder since the 1960s. In the US, methadone clinics are tightly regulated by the Drug Enforcement Administration and the Substance Abuse and Mental Health Services Administration. Patients receiving methadone to treat their addiction must ingest it under the observation and supervision of clinic staff, who keep it in a lock box. Eventually, patients are permitted to take a few doses home with them for use over the weekend, a...
Source: Cato-at-liberty - February 25, 2019 Category: American Health Authors: Jeffrey A. Singer Source Type: blogs

The Revolving Door Spins Again: the Now Constant Coziness Between the Health Care Industry and US Government
Just because Washington DC is now crazy town does not mean the revolving door has stopped spinning. We have been dutifully accumulating cases, so it is time to present our latest update.I will divide this into two sections 1) the incoming revolving door, through which come people from the health care industry to enter US government positions in which they may influence health care regulation or policy relevant to their former positions; and 2) the outgoing revolving door, through which go people from US government positions in which they influenced health care regulation or policy to industry positions which were rel...
Source: Health Care Renewal - February 22, 2019 Category: Health Management Tags: DHHS Donald Trump FDA revolving doors Source Type: blogs

SRNT Under Fire for Accepting Sponsorship Money from E-Cigarette Company for Annual Meeting
Controversy is brewing in San Francisco this week as it was revealed that the Society for Research on Nicotine and Tobacco (SRNT) accepted money from an e-cigarette company to sponsor its annual meeting which is being held this week.It was reported this morning that SRNT accepted funding from GreenSmokeKloud, an e-liquid distributor whose products are competing with nicotine replacement therapy and Chantix for a share of the smoking cessation market.Critics pointed out that sponsorship of the conference by GreenSmokeKloud presents a severe conflict of interest because its products are being used for smoking cessation and t...
Source: The Rest of the Story: Tobacco News Analysis and Commentary - February 21, 2019 Category: Addiction Source Type: blogs

Instagram Influencers Promote Prescription Drugs; FDA's Continuing Monitoring
The FDS has warned pharmaceutical companies in the past about their use of paid surrogates on social media sites like Instagram to promote their products (see:Pharmaceutical Companies Continue to Experiment with Social Media;FDA Issues Warning Letter to Drug Company about Use of Instagram;GlaxoSmithKline Mines Social Media for Information about Adverse Drug Events). This issue has recently returned to the news (see:The latest Instagram influencer frontier? Medical promotions. Big pharma is partnering with influencers to sell new drugs and medical devices). Below is an excerpt from the article. It's long and provides ma...
Source: Lab Soft News - February 20, 2019 Category: Laboratory Medicine Authors: Bruce Friedman Source Type: blogs

Spravato: New Ketamine Treatment to be Approved by FDA
Last week a committee of the U.S. Food and Drug Administration (FDA) recommended in a 14-2 vote that the agency approve the use of a nasal spray form of esketamine (a specific type of ketamine) for the treatment of treatment-resistant depression and certain other types of depression. Treatment-resistant depression is when clinical depression fails to respond to multiple (at least two) attempts to treat it with at least two different types of medications or psychotherapy over the course of a year or longer. If the FDA ends up approving the drug — and we believe they will — it will offer new hope for people with ...
Source: World of Psychology - February 20, 2019 Category: Psychiatry & Psychology Authors: John M. Grohol, Psy.D. Tags: Depression Disorders General Medications Treatment esketamine ketamine for depression Spravato Suicide TRD Treatment Resistant Depression Treatment-resistant Source Type: blogs